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DNA methylation changes are associated with cigarette smoking. We used the Illumina Infinium HumanMethylation450 array
to determine whether methylation in DNA from pre-diagnostic, peripheral blood samples is associated with lung cancer risk.
We used a case-control study nested within the EPIC-Italy cohort and a study within the MCCS cohort as discovery sets
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(a total of 552 case-control pairs). We validated the top signals in 429 case-control pairs from another 3 studies. We identi-
fied six CpGs for which hypomethylation was associated with lung cancer risk: cg05575921 in the AHRR gene
(p-valuepooled54 3 10
217), cg03636183 in the F2RL3 gene (p-valuepooled52 3 10
2 13), cg21566642 and cg05951221 in
2q37.1 (p-valuepooled57 3 10
216 and 1 3 10211 respectively), cg06126421 in 6p21.33 (p-valuepooled52 3 10
215) and
cg23387569 in 12q14.1 (p-valuepooled55 3 10
27). For cg05951221 and cg23387569 the strength of association was virtually
identical in never and current smokers. For all these CpGs except for cg23387569, the methylation levels were different across
smoking categories in controls (p-valuesheterogeneity1.8 x10
2 7), were lowest for current smokers and increased with time
since quitting for former smokers. We observed a gain in discrimination between cases and controls measured by the area
under the ROC curve of at least 8% (p-values0.003) in former smokers by adding methylation at the 6 CpGs into risk
prediction models including smoking status and number of pack-years. Our findings provide convincing evidence that smoking
and possibly other factors lead to DNA methylation changes measurable in peripheral blood that may improve prediction of
lung cancer risk.
Smoking is the main cause of lung cancer with attributable
risks of at least 85% for men and 60% for women,1,2 yet a
signiﬁcant number of cases cannot be attributed either to
cigarette smoking or other established risk factors such as air
pollution. The major mechanisms considered to explain the
effect of cigarette smoking on lung cancer risk include the
exposure to carcinogenic compounds, the formation of DNA
adducts and the accumulation of permanent somatic muta-
tions in tumor suppressor genes and dominant oncogenes3.
The balance between metabolic activation and detoxiﬁcation
of carcinogens varies between individuals and this is likely to
be at least partly responsible for the variation in susceptibility
to lung cancer among smokers.
Alterations of the methylation proﬁle of DNA from periph-
eral blood associated with cigarette smoking have been recently
described4–11. The altered DNA methylation levels persist long
after smoking cessation for some genomic locations (i.e. CpGs)
while for others return to those of never-smokers12. Recently,
using a study conducted within the NOWAC cohort as discov-
ery data set and studies within the Australian MCCS cohort,
the Swedish NSHDS and the EPIC-Heidelberg cohort as
replication sets, we observed that smoking-associated DNA
methylation alterations in CpGs in the AHRR and F2RL3 genes
are associated with lung cancer risk13; the association with
alterations in DNA methylation in F2RL3 was also reported in
a recent German study14. Our study provided initial suggestive
biological plausibility and statistical evidence that these epige-
netic alterations may partly mediate the effect of smoking on
lung cancer risk13.
In order to identify novel DNA methylation changes asso-
ciated with lung cancer risk and better understand the mech-
anisms underlying these associations, we conducted a further
analysis of the four epigenome-wide association studies
(EWAS) in NOWAC, MCCS, NSHDS, EPIC-Heidelberg and
in a new, independent EWAS in the EPIC-Italy cohort that
became available recently. In all these ﬁve case-control stud-
ies nested within prospective cohorts, we investigated associa-
tions between methylation of DNA from pre-diagnostic,
peripheral blood samples and lung cancer risk accounting for
reported smoking habits.
Methods
Discovery and replication sets
To test our hypotheses regarding the relationship between
DNA methylation and lung cancer risk, we used data from a
new EWAS within the Italian component of the European
Prospective Investigation into Cancer15 (EPIC-Italy)16 and a
previous one within the Melbourne Collaborative Cohort
Study (MCCS)17 as discovery sets and data from previous
EWAS from the Norwegian Women and Cancer study
(NOWAC)13, the Northern Sweden Health and Disease Study
(NSHDS)18 and EPIC-Heidelberg19 as replication sets. All ﬁve
studies were case–control studies nested within prospective
cohorts including 367, 185, 132, 234, and 63 case–control pairs
respectively for which methylation was measured using the
Illumina Inﬁnium Human Methylation 450 BeadChip on DNA
extracted from prediagnostic, peripheral blood samples. Rela-
tive to our previous report13, here we present the new study
within EPIC-Italy as well as the complete data from the MCCS
that in the previous report was used only to replicate the signals
in the AHRR and F2RL3 genes. For all studies one control was
individually matched to each case. In MCCS and NSHDS con-
trols were matched to cases by reported smoking status at blood
draw using ﬁve categories (never smokers; short-term former
What’s new?
It is well known that smoking can cause lung cancer but the concept that it might do so by changing DNA methylation is only
emerging. Here the authors identify six sites of methylation (CpGs), where methylation levels were associated with lung cancer
risk after adjusting for smoking, current or former. Methylation of five of the CpGs was lowest in current smokers and
increased in former smokers with time since quitting, supporting the growing evidence that smoking may lead to DNA methyl-
ation changes measurable in peripheral blood and useful as predictive markers for lung cancer risk, especially in former
smokers.
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smokers: quitting smoking <10 years before; long-term former
smokers: quitting smoking 10 years or more before; current
light smokers: <15 cigarettes per day; and current heavy smok-
ers: 15 cigarettes or more) in EPIC-Heidelberg they were
matched by reported smoking status in two categories (current
and former) and number of pack-years. In EPIC-Italy and
NOWAC controls were not matched by smoking. Further
details for each study are provided in the Supplementary
Materials.
Laboratory methods, data pre-processing
and quality control
Laboratory methods for DNA extraction, quality control, bisul-
phite conversion and Illumina Inﬁnium HumanMethyla-
tion450 BeadChip assays as well as details about data pre-
processing and quality control are described in detail in the
Supplementary Materials and were broadly similar across stud-
ies. Exceptions are noted explicitly. For the MCCS some DNA
samples were extracted from dried blood spots on Guthrie
cards using a method developed in-house20. Cases with DNA
available only from dried blood spots were matched to controls
with the same type of DNA available.
Normalisation procedures of the methylation measures
were applied to perform colour channel and probe type correc-
tion as described in the Supplementary Materials.
Statistical analysis
For all analyses we used M-values of methylation calculated as
log2(beta/(1-beta))
21. To quantify the association between the
methylation level at each CpG and the risk of lung cancer we
ﬁtted conditional logistic regression models separately for the
two discovery sets, the MCCS and EPIC-Italy. For EPIC-Italy,
for which smoking was not a matching variable, we adjusted
the regression models for smoking. In the regression models,
we included as a predictor the pseudo-continuous M-value of
methylation at each CpG that we obtained by dividing the M-
values into quartiles according to the distribution in the control
group and assigning to each category the within-quartile medi-
an value. We estimated odds ratios per 1 standard deviation
(SD) of the pseudo-continuous variable and the corresponding
95% conﬁdence intervals (95% CI).
We ranked the CpGs according to the p-values of the corre-
sponding ORs, separately for MCCS and EPIC-Italy, and iden-
tiﬁed 34 CpGs with a p values lower than 1024 for at least one
study. For these CpGs we calculated pooled MCCS and EPIC-
Italy estimates and selected for further analyses and replication
6 CpGs whose combined estimate had a p values lower than
1025. For the selected 6 CpGs and for the previously identiﬁed
cg03636183 in the F2RL3 gene, we estimated the ORs for lung
cancer separately for MCCS, EPIC-Italy and the three replica-
tion studies. For this set of seven CpGs, we estimated pooled
ORs by combining the study-speciﬁc estimates ﬁtting ﬁxed
effect models overall and for different categories of smoking
(never, former and current). We adjusted the estimates for cur-
rent and former smokers for number of cigarettes and duration
of smoking and the estimates for former smokers also for time
since quitting smoking. We estimated ORs for different catego-
ries of time to diagnosis and used a likelihood ratio test to test
for heterogeneity. We assessed the possible effect of cell compo-
sition on the results by adding into the models the proportions
of different cell types (CD81, CD41, natural killer cells,
B-cells, monocytes, granulocytes) calculated using the method
suggested by Houseman22.
We also estimated the association betweenM-values of meth-
ylation and reported smoking for the control group by ﬁtting a
linear mixed effect model with slide (i.e. chip) nested within plate
ﬁtted as random effects and gender, age at blood collection and
smoking ﬁtted as ﬁxed effects. We used likelihood ratio tests to
test the association between methylation and smoking.
We evaluated separately for the MCCS and EPIC-Italy the
additional contribution of DNAmethylation at the CpGs associat-
ed with lung cancer risk to the ability of the model to discriminate
between cases and controls using area under the curve (AUC) sta-
tistics obtained from unconditional logistic regression models
adjusted for the matching variables. We accounted for the contri-
bution of smoking by including among the covariates smoking
status and the number of pack-years of cigarettes smoked.
Finally, for the CpGs whose pooled estimates had an OR
with a p values of<1027, we investigated graphically the associ-
ation between DNA methylation and lung cancer risk in the
100 kilobase region around each CpG site, by plotting the
pooled MCCS and EPIC ORs versus the CpG location.
Results
Genome-wide association analysis in the
two discovery sets
Relative to the total number of CpGs investigated across the
genome, the proportion of CpGs with methylation levels inverse-
ly associated with lung cancer risk was 55% in the new EPIC-
Italy study and 53% in MCCS. Overall, for 48% of the CpGs we
observed concordant associations between methylation level and
lung cancer risk in MCCS and EPIC-Italy (either both negative
or both positive) and of these 58% were concordant negative.
We identiﬁed 34 CpGs for which the smoking-adjusted
association with lung cancer risk corresponds to a p values
lower than 1024 in at least one of the two studies (Support-
ing Information Fig. 1), and these are presented in Table 1
with their ORs and p-values. Of these CpGs, 22 were from
MCCS, 9 from EPIC-Italy and 3 were common to both stud-
ies: cg21566642 on chromosome 2, cg05575921 in the AHRR
gene on chromosome 5 and cg06126421 on chromosome 6.
Table 1 also presents the estimates for cg03636183 in the
gene F2RL3 on chromosome 19, that, together with
cg05575921 in the AHRR gene we previously reported to be
associated with lung cancer risk13.
Of the associations corresponding to the 34 CpGs listed in
Table 1, 73%; (95% CI, 54% to 86%, p5 0.01) were concor-
dant in the two studies and, of these, 79% (95% CI, 0.57% to
0.92%, p5 0.008) were concordant negative (Supporting
Information Fig. 1-right panel).
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Table 1. “Top CpGs” in the two case-control studies nested within the EPIC-Italy and MCCS cohorts (discovery sets)
UCSC_
REFGENE
EPIC-Italy (185 case-control pairs) MCCS (367 case-control pairs) Pooled estimate
TargetID1 MAPINFO CHR OR (95% CI) p values rank OR (95% CI) p values Rank OR (95% CI) p values
cg03256938 2983926 FLJ42875 1 0.93 (0.68-1.27) 6.56E-01 313561 1.59 (1.29-1.97) 1.65E-05 5 1.35 (1.13-1.6) 9.04E-04
cg18146737 92946700 GFI1 1 0.38 (0.25-0.57) 4.35E-06 2 0.85 (0.71-1.02) 8.33E-02 37354 0.75 (0.64-0.88) 6.34E-04
cg059512212 233284402 2 0.4 (0.27-0.61) 1.89E-05 6 0.69 (0.55-0.86) 9.01E-04 264 0.61 (0.5-0.74) 7.74E-07
cg215666422 233284661 2 0.45 (0.32-0.64) 9.97E-06 3 0.61 (0.48-0.77) 3.88E-05 15 0.55 (0.45-0.67) 3.93E-09
cg12749468 183755507 HTR3D 3 – – – 0.61 (0.48-0.77) 3.80E-05 12 0.61 (0.48-0.77) 3.80E-05
cg10663765 194014592 3 0.85 (0.58-1.24) 3.86E-01 192168 0.67 (0.56-0.8) 1.87E-05 6 0.7 (0.59-0.83) 2.35E-05
cg02901723 91049728 FAM190A 4 2.87 (1.74-4.72) 3.58E-05 8 1.07 (0.86-1.34) 5.45E-01 262091 1.27 (1.03-1.55) 2.46E-02
cg23916896 368804 AHRR 5 0.49 (0.35-0.68) 1.79E-05 5 0.84 (0.7-1.01) 6.61E-02 29301 0.73 (0.62-0.86) 1.92E-04
cg055759212 373378 AHRR 5 0.41 (0.29-0.57) 2.48E-07 1 0.61 (0.48-0.78) 8.49E-05 20 0.53 (0.43-0.65) 5.26E-10
cg26853442 161178531 5 1.05 (0.79-1.4) 7.29E-01 346039 0.64 (0.52-0.79) 3.12E-05 10 0.76 (0.64-0.9) 1.53E-03
cg01882991 6677756 6 0.44 (0.3-0.63) 1.12E-05 4 0.92 (0.75-1.12) 4.10E-01 196120 0.77 (0.65-0.92) 4.44E-03
cg061264212 30720080 6 0.48 (0.34-0.68) 4.49E-05 10 0.61 (0.49-0.75) 2.32E-06 1 0.57 (0.48-0.68) 8.46E-10
cg20421191 33217620 6 0.95 (0.66-1.36) 7.77E-01 367218 1.58 (1.26-1.99) 8.87E-05 21 1.37 (1.13-1.66) 1.62E-03
cg21984374 166290219 6 0.96 (0.71-1.29) 7.66E-01 362359 0.67 (0.55-0.81) 3.29E-05 11 0.74 (0.63-0.87) 2.57E-04
cg14586887 28966691 7 1.09 (0.74-1.58) 6.71E-01 320421 1.59 (1.28-1.97) 2.87E-05 8 1.45 (1.2-1.75) 1.23E-04
cg14371343 122097744 CADPS2 7 0.94 (0.69-1.26) 6.60E-01 315632 0.61 (0.48-0.77) 3.82E-05 13 0.72 (0.6-0.86) 4.45E-04
cg17528127 144332475 ZFP41 8 0.97 (0.71-1.32) 8.57E-01 402485 0.64 (0.51-0.8) 9.62E-05 25 0.74 (0.61-0.89) 1.17E-03
cg01843018 123813144 C5 9 0.51 (0.37-0.72) 8.27E-05 12 0.98 (0.79-1.22) 8.53E-01 413423 0.81 (0.67-0.97) 2.07E-02
cg17171127 130248270 11 1.03 (0.77-1.37) 8.64E-01 405797 0.65 (0.52-0.8) 7.86E-05 19 0.76 (0.64-0.91) 2.34E-03
cg16823042 58119992 AGAP2 12 0.79 (0.58-1.08) 1.37E-01 73212 0.69 (0.57-0.83) 8.94E-05 22 0.71 (0.6-0.84) 3.73E-05
LOC100130776
cg233875692 58120011 AGAP2 12 0.82 (0.6-1.12) 2.20E-01 114030 0.67 (0.56-0.8) 9.51E-06 3 0.7 (0.6-0.82) 8.47E-06
LOC100130776
cg00873601 116044025 12 1.97 (1.43-2.72) 3.86E-05 9 1.01 (0.85-1.2) 9.19E-01 446272 1.17 (1.01-1.37) 4.07E-02
cg18754747 133526522 ZNF605 12 0.97 (0.72-1.32) 8.59E-01 403456 0.63 (0.51-0.78) 2.87E-05 9 0.73 (0.61-0.87) 4.18E-04
cg03261929 79168211 13 0.94 (0.71-1.24) 6.57E-01 314009 0.66 (0.54-0.81) 6.94E-05 18 0.75 (0.63-0.88) 4.86E-04
cg123128632 2569967 AMDHD2 16 0.79 (0.58-1.07) 1.21E-01 65012 0.63 (0.52-0.77) 4.00E-06 2 0.67 (0.57-0.79) 2.35E-06
ATP6V0C
cg06279276 67184164 B3GNT9 16 1.23 (0.9-1.69) 1.99E-01 103877 0.67 (0.56-0.81) 3.82E-05 14 0.79 (0.67-0.93) 4.02E-03
cg16674433 19314408 RNF112 17 0.91 (0.64-1.28) 5.78E-01 278940 0.69 (0.57-0.83) 6.31E-05 16 0.73 (0.62-0.86) 1.52E-04
cg12076915 42430253 19 0.77 (0.55-1.07) 1.17E-01 63132 0.7 (0.58-0.83) 9.33E-05 24 0.71 (0.61-0.84) 2.93E-05
cg21727574 53098913 ZNF137 19 1.11 (0.8-1.52) 5.35E-01 259711 0.57 (0.44-0.75) 6.47E-05 17 0.76 (0.62-0.93) 8.67E-03
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For six CpGs (cg05951221, cg21566642, cg05575921,
cg06126421, cg23387569 and cg12312863) the pooled ORs
for lung cancer across EPIC-Italy and MCCS had a p values
lower than 1025 (Table 1). For these six CpGs and for
cg03636183 in the F2RL3 gene, we tested the association with
lung cancer risk in another three independent studies within
NOWAC, EPIC-Heidelberg and NSHDS (Fig. 1) by estimat-
ing the associations for each study separately and deriving
pooled ORs across the ﬁve studies. For 6 of the 7 CpGs the
pooled ORs had a p values lower than 5 3 1027: cg05951221
(pooled OR per 1 SD of methylation change5 0.59; 95% CI:
0.51-0.69, p5 1.23 3 10211); cg21566642 (pooled OR per 1
SD, 0.53; 95% CI, 0.45-0.62; p, 6.54 3 10216); cg05575921
(pooled OR per 1 SD, 0.50; 95% CI, 0.43-0.59; p, 4.30 3
10217); cg06126421 (pooled OR per 1 SD, 0.58; 95% CI,
0.51-0.67; p, 2.34 3 10215); cg23387569 (pooled OR per 1
SD,0.74; 95% CI, 0.66–0.83; 4.67 3 1027); cg03636183
(pooled OR per 1 SD, 0.60; 95% CI, 0.52–0.68; p, 2.09 3
10213) (Table 2 and Fig. 1). For these six CpGs, the results
did not materially change when the analyses were adjusted
for estimated cell composition (Supporting Information
Tables 1 and 2); we did not observe heterogeneity in the ORs
for lung cancer between studies (all p-values for hetero-
geneity 0.1, Fig. 1) or by time between blood draw and
diagnosis overall or by smoking status (Supporting Informa-
tion Table 3).
Associations with reported smoking history and
associations with lung cancer risk by smoking category
Of the six CpGs associated with lung cancer risk, the methyl-
ation levels of ﬁve (cg05951221, cg21566642, cg05575921,
cg06126421, and cg03636183) were strongly associated with
reported smoking history in the control groups (p-values for
heterogeneity across smoking categories all 1.8 3 1027).
DNA methylation levels were lowest for current smokers
while average levels for former smokers were intermediate
between those for current and never smokers; DNA methyla-
tion levels for former smokers increased with increasing time
since quitting (Table 3; Supporting Information Figs. 2 and 3).
To investigate whether the association between methyla-
tion levels at the 6 CpGs and lung cancer risk could be due
to residual confounding by smoking, we conducted stratiﬁed
analyses by smoking status separately for each of the ﬁve
studies and overall (Table 2). For all the CpGs the pooled
ORs were lower than unity for former and current smokers
and the ORs were consistently lower for former smokers
than for current smokers; for all CpGs the OR for never
smokers was nominally lower than unity but none of the
ORs for never smokers were statistically signiﬁcant.
Ability of methylation levels to predict lung cancer risk
For EPIC-Italy, the value of the AUC for the model including
reported smoking status (categorised as never, former and
current smoker) and the number of pack years was 79%.
Adding methylation levels for each CpG individually resultedTa
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in gains of 1.8% for cg05575921, 1.3% for cg06126421 and
<1% for each of the other selected CpGs (Table 4 and Sup-
porting Information Fig. 4). When methylation levels for all
the 6 CpGs were included simultaneously in the model, their
additional contribution to lung cancer risk prediction was
2.6% (p5 0.034) overall; 11.1% (p5 0.011) in former smok-
ers and 1.2% in current smokers (p5 0.52). We obtained
similar results from the MCCS in which the overall gain
from including all the CpGs combined was 5.5% (p5 0.002)
relative to the model including smoking history (categorized
as never smokers; former smokers who stopped <10 years
before blood draw; former smokers who stopped 10 or more
years before blood draw; current smokers who smoked <15
cigarettes per day; and current smokers who smoked 15 or
more cigarettes per day) and number of pack-years; the gain
was 7.6% (p5 0.004) in former smokers and 3.3% (p5 0.28)
in current smokers.
Analyses of regions around the CpGs associated
with lung cancer risk
Both cg05951221 and cg21566642 are located in a CpG
island on chromosome 2q37.1 in which a region with differ-
ential methylation between cases and controls is clearly visi-
ble (Fig. 2a); this region extends for approximately 2
kilobases and includes 8 CpGs for which lower methylation
levels are associated with an increased risk of lung cancer.
The correlation between the methylation M-values for
cg05951221 and cg21566642 (259 bases apart) was 0.80 and
for cg21566642 and cg01940273 (273 bases apart) was 0.75.
The 100k-base region around cg05951221 and cg21566642
contains three genes (ALPPL2, ALPP, and ALP-1, and
ECEL1) and the pseudogene ECEL1P2 whose methylation has
been found to increase through development23. Alkaline
phosphatases (ALPs) dephosphorylate a variety of molecules
such as proteins, nucleotides and alkaloids. Serum ALPP and
Figure 1. Estimated ORs for lung cancer risk for one SD increment in M methylation values separately for each of the five studies and over-
all (pooled estimates) for the 6 CpGs with pooled ORs across MCCS and EPIC-Italy with p<10E-5 and cg03636183 in F2RL3.
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Table 2. Association between methylation levels and lung cancer risk in the 5 nested case-control studies and pooled odds ratios (OR)
estimated overall and by level of smoking
All Never Former Current
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
cg05951221
EPIC-Italy 0.40 (0.27-0.61) 1.89E-05 0.95 (0.26-3.44) 9.36E-01 0.02 (0.00-1.24) 6.27E-02 0.55 (0.09–3.38) 5.19E-01
MCCS 0.69 (0.55-0.86) 9.01E-04 0.54 (0.25-1.2) 1.30E-01 0.59 (0.39-0.89) 1.25E-02 0.87 (0.62–1.21) 4.13E-01
NOWAC 0.60 (0.35-1.02) 5.76E-02 1.51 (0.18-12.76) 7.08E-01 0.10 (0.01-1.41) 8.74E-02 0.52 (0.15–1.82) 3.08E-01
EPIC-Heidelberg 0.64 (0.35-1.18) 1.54E-01 – – 0.23 (0.03-2.03) 1.87E-01 0.68 (0.35–1.32) 2.54E-01
NSHDS 0.54 (0.40-0.72) 4.97E-05 0.85 (0.47-1.54) 5.95E-01 0.60 (0.35-1.02) 5.89E-02 0.67 (0.49–0.92) 1.29E-02
Pooled 0.59 (0.51-0.69) 1.23E-11 0.77 (0.5-1.19) 2.40E-01 0.56 (0.40-0.77) 3.12E-04 0.74 (0.60-0.91) 5.04E-03
cg21566642
EPIC-Italy 0.45 (0.32-0.64) 9.97E-06 1.55 (0.25-9.75) 6.38E-01 0.31 (0.08-1.29) 1.08E-01 0.66 (0.22-2.00) 4.62E-01
MCCS 0.61 (0.48-0.77) 3.88E-05 0.76 (0.38-1.51) 4.31E-01 0.52 (0.33-0.82) 4.91E-03 0.72 (0.5-1.05) 8.79E-02
NOWAC 0.54 (0.32-0.90) 1.73E-02 1.1 (0.19-6.56) 9.13E-01 0.11 (0.01-1.65) 1.09E-01 0.91 (0.29-2.82) 8.69E-01
EPIC-Heidelberg 0.54 (0.30-0.98) 3.94E-02 – – 0.70 (0.17-3.01) 6.35E-01 0.49 (0.24-0.99) 4.57E-02
NSHDS 0.46 (0.34-0.64) 3.29E-06 0.83 (0.43-1.59) 5.78E-01 0.52 (0.28-0.96) 3.80E-02 0.49 (0.33-0.73) 4.40E-04
Pooled 0.53 (0.45-0.62) 6.54E-16 0.84 (0.54-1.32) 4.55E-01 0.50 (0.36-0.71) 7.47E-05 0.60 (0.47-0.77) 3.72E-05
cg05575921
EPIC-Italy 0.41 (0.29-0.57) 2.48E-07 0.57 (0.06-5.73) 6.35E-01 0.3 (0.09-0.96) 4.22E-02 0.69 (0.22-2.21) 5.34E-01
MCCS 0.61 (0.48-0.78) 8.49E-05 0.53 (0.18-1.56) 2.50E-01 0.56 (0.36-0.87) 1.01E-02 0.73 (0.51-1.03) 7.71E-02
NOWAC 0.37 (0.19-0.71) 2.87E-03 0.06 (0-19.26) 3.45E-01 – – 0.31 (0.06-1.51) 1.46E-01
EPIC-Heidelberg 0.72 (0.36-1.46) 3.69E-01 – – 0.29 (0.03-3.32) 3.23E-01 0.70 (0.31-1.59) 3.84E-01
NSHDS 0.43 (0.31-0.60) 4.91E-07 1.66 (0.71-3.84) 2.40E-01 0.43 (0.24-0.77) 4.25E-03 0.59 (0.42-0.82) 1.78E-03
Pooled 0.50 (0.43-0.59) 4.30E-17 0.99 (0.53-1.87) 9.82E-01 0.48 (0.35-0.67) 1.74E-05 0.65 (0.52-0.81) 1.41E-04
cg06126421
EPIC-Italy 0.48 (0.34-0.68) 4.49E-05 0.34 (0.09-1.29) 1.12E-01 0.41 (0.11-1.55) 1.90E-01 0.92 (0.31-2.73) 8.75E-01
MCCS 0.61 (0.49-0.75) 2.32E-06 0.49 (0.21-1.17) 1.10E-01 0.65 (0.45-0.93) 1.84E-02 0.67 (0.50-0.90) 8.09E-03
NOWAC 0.58 (0.37-0.91) 1.86E-02 0.74 (0.2-2.82) 6.62E-01 0.50 (0.10-2.55) 4.02E-01 0.45 (0.13-1.51) 1.96E-01
EPIC-Heidelberg 0.22 (0.10-0.50) 3.54E-04 – – 0.30 (0.06-1.43) 1.29E-01 0.16 (0.05-0.50) 1.76E-03
NSHDS 0.65 (0.51-0.82) 3.51E-04 1.3 (0.72-2.37) 3.87E-01 0.56 (0.36-0.89) 1.35E-02 0.7 (0.51-0.94) 1.85E-02
Pooled 0.58 (0.51-0.67) 2.34E-15 0.83 (0.54-–1.28) 4.01E-01 0.59 (0.45–0.77) 1.05E-04 0.65 (0.53-0.8) 3.20E-05
cg23387569
EPIC-Italy 0.82 (0.60-1.12) 2.20E-01 1 (0.44-2.31) 9.96E-01 2.97 (0.81-10.9) 1.00E-01 1.3 (0.38-4.45) 6.78E-01
MCCS 0.67 (0.56-0.80) 9.51E-06 0.53 (0.3-0.96) 3.58E-02 0.47 (0.32-0.7) 1.93E-04 0.79 (0.62-1.01) 6.05E-02
NOWAC 0.76 (0.49-1.18) 2.20E-01 1.18 (0.2-7.02) 8.55E-01 1.54 (0.17-13.66) 7.01E-01 0.76 (0.38-1.55) 4.53E-01
EPIC-Heidelberg 0.54 (0.30-0.98) 3.94E-02 – – 0.7 (0.17-3.01) 6.35E-01 0.49 (0.24-0.99) 4.57E-02
NSHDS 0.84 (0.68-1.03) 9.17E-02 0.87 (0.48-1.56) 6.39E-01 0.86 (0.57-1.29) 4.65E-01 0.85 (0.61-1.17) 3.08E-01
Pooled 0.74 (0.66-0.83) 4.67E-07 0.75 (0.52-1.08) 1.21E-01 0.69 (0.52-0.9) 6.31E-03 0.79 (0.66-0.94) 9.73E-03
cg03636183
EPIC-Italy 0.59 (0.45-0.78) 1.97E-04 0.2 (0.03-1.42) 1.09E-01 0.44 (0.18-1.05) 6.48E-02 0.48 (0.14-1.71) 2.58E-01
MCCS 0.67 (0.54-0.84) 3.63E-04 0.73 (0.38-1.4) 3.43E-01 0.66 (0.45-0.97) 3.35E-02 0.8 (0.57-1.13) 2.08E-01
NOWAC 0.47 (0.29-0.78) 3.22E-03 0.58 (0.01-39.48) 8.03E-01 0.25 (0.04-1.53) 1.33E-01 0.64 (0.24-1.67) 3.60E-01
EPIC-Heidelberg 0.66 (0.37-1.16) 1.46E-01 – – 0.26 (0.02-2.92) 2.75E-01 0.73 (0.4-1.35) 3.15E-01
NSHDS 0.52 (0.39-0.69) 9.70E-06 1.42 (0.73-2.76) 2.96E-01 0.41 (0.22-0.73) 2.81E-03 0.66 (0.46-0.94) 2.22E-02
Pooled 0.60 (0.52-0.68) 2.09E-13 0.93 (0.59-1.45) 7.35E-01 0.54 (0.4-0.72) 3.76E-05 0.72 (0.58-0.89) 2.95E-03
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ALPPL2 enzyme levels are increased in heavy smokers and in
cancer, particularly in seminoma24.
We observed no signiﬁcant correlation between
cg05575921, located within the AHRR gene on chromosome
5p15.33, and the nearby CpGs (Fig. 2b). In the 100 kilobases
ﬂanking the probe maps one more gene (EXOC3) that codes
for a component of the exocyst complex and its antisense
RNA (EXOC3-AS1).
The probe cg06126421 on chromosome 6p21.33 is ﬂanked
by a region extending approximately 200 bases containing
another 5 CpGs whose methylation levels correlate with meth-
ylation levels of cg06126421 (correlations ranging from 0.44 to
0.67) (Fig. 2c). In the 100 kilobases ﬂanking cg06126421 there
are seven genes that code for proteins involved in cell cycle
checkpoints in response to DNA damage (MDC1), cellular
growth and division (DHX16), protection of cells from Fas- or
tumor necrosis factor type alpha-induced apoptosis (IER3),
cytoskeleton regulation and membrane trafﬁc (PPP1R18,
TUBB, FLOT1, NRM). In particular, FLOT1 mRNA expression
has been shown to be upregulated in non-small cell lung cancer
tissue25. Also, two long non-coding RNAs (lncRNAs) map in
the region:MDC1-AS1 and LINC00243.
A region of 300 bases extends around cg23387569 on
chromosome 12q14.1 as methylation levels for the six CpG
sites in this region quite strongly correlate with methylation
level at cg23387569 (correlations ranging from 0.52 to 0.87)
(Fig. 2d). The region is located in a CpG island within the
AGAP2 gene, which encodes a protein belonging to the cen-
taurin gamma-like family that mediates anti-apoptotic effects
of nerve growth factor by activating nuclear phosphoinositide
3-kinase. The AGAP2 gene is overexpressed in cancer cells,
and promotes cancer cell invasion. The region surrounding
cg23387569 has been previously found ampliﬁed in lung can-
cer26 together with other four genes that map in the region
(CDK4, CYP27B1, METTL1, and TSFM). One of them codes
for the cyclin-dependent kinase 4, a member of the Ser/Thr
protein kinase family that is important for cell cycle G1–S
transition by the RB1–CCND1–CDKN2A pathway that is
known to be damaged in lung cancer.
Other genes in the 100-kilobase region include AVIL,
B4GALNT1, OS9, TSPAN31, MARCH9, METTL21B, TSPAN31
and two miRNAs: MIR6759 and MIR26A2
We observed no correlation between cg03636183, located
within the F2RL3 gene on chromosome 19p13.11, and the
nearby CpGs (Fig. 2e).
Discussion
This new analysis, combining data from the four EWAS that
previously allowed us to identify the ﬁrst two CpGs in AHRR
and F2RL3 associated with lung cancer risk with previously
unpublished new data from a novel EWAS in EPIC-Italy, led to
the discovery of four additional CpGs and showed that methyl-
ation at these CpGs may be useful to improve current risk
prediction models based on self-reported smoking history.
Table 3. Association between methylation levels and smoking status in controls from EPIC-Italy and MCCS at the 6 CpGs associated with
lung cancer risk
EPIC-Italy MCCS
Probe Smoking coef (95% CI) p p-het1 coef (95% CI) p p-het1
cg05951221 Never Reference - 1.59E-13 Reference - 1.18E-21
Former 20.27 (20.39, 20.16) 7.28E-06 20.3 (20.44, 20.16) 3.05E-05
Current 20.54 (20.68, 20.41) 1.23E-13 20.63 (20.76, 20.49) 6.18E-18
cg21566642 Never reference - 7.98E-17 reference - 9.99E-32
Former 20.34 (20.48, 20.2) 3.00E-06 20.3 (20.45, 20.14) 2.13E-04
Current 20.77 (20.93, 20.6) 4.45E-17 20.82 (20.98, 20.67) 7.73E-23
cg05575921 Never reference - 1.98E-15 reference - 1.67E-40
Former 20.27 (20.48, 20.07) 9.42E-03 20.24 (20.44, 20.03) 2.29E-02
Current 21.07 (21.3, 20.83) 7.28E-16 21.12 (21.32, 20.92) 3.47E-24
cg06126421 Never Reference - 1.81E-07 Reference - 3.85E-13
Former 20.23 (20.4, 20.06) 7.96E-03 20.34 (20.56, 20.12) 2.70E-03
Current 20.57 (20.77, 20.38) 4.64E-08 20.74 (20.95, 20.52) 6.19E-11
cg23387569 Never Reference - 7.37E-04 Reference - 1.23E-01
Former 20.39 (20.67, 20.11) 6.32E-03 0.02 (20.25, 0.29) 8.91E-01
Current 20.57 (20.9, 20.25) 5.92E-04 20.15 (20.42, 0.11) 2.65E-01
cg03636183 Never Reference - 1.28E-11 Reference - 1.18E-23
Former 20.16 (20.27, 20.04) 7.04E-03 20.22 (20.38, 20.07) 4.30E-03
Current 20.5 (20.64, 20.37) 3.18E-12 20.67 (20.82, 20.52) 1.14E-16
1p values of the test of homogeneity by smoking.
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Our previous report that DNA methylation changes at
cg05575921 in the AHRR gene and at cg03636183 in the
F2RL3 gene were associated with lung cancer risk13 included
mediation analyses which provided initial suggestive evidence
that residual confounding was unlikely to explain the
observed associations for cg05575921 and cg03636183, and
that hypomethylation at these two sites may mediate the
effect of tobacco on lung cancer risk. For cg03636183, an
association with lung cancer risk similar to the one we
observed was also reported in a study of 4,987 participants in
the German ESTHER cohort, of which 97 developed lung
cancer during a median follow-up of around 11 years14. In
ESTHER only three CpGs in the F2RL3 gene, including
cg03636183, were measured using mass-spectrometry (i.e.
MALDI-TOF) and were targeted because of the established
strong association between cigarette smoking and methylation
at this site.
Relative to our previous report13, in the present analyses
we have included data from a new case-control study nested
within EPIC-Italy and presented the complete data from the
MCCS that was previously utilised only to validate the CpGs
within the AHRR and F2RL3 genes; consequently, the results
reported here for all other CpGs can be considered original
and independent from those previously published. To investi-
gate the possible role of smoking in explaining the observed
associations between DNA methylation and lung cancer risk,
we deliberately oversampled cases of former and never smok-
ers from some of the cohorts.
The associations we observed between DNA methylation
and lung cancer risk are relatively strong (ORs for 1 SD
increase in DNA methylation are between 0.74 and 0.50),
they are not limited to current smokers and they remained
strong after adjusting for smoking duration and intensity:
this suggests that the associations between DNA methylation
and lung cancer risk are unlikely to be explained by residual
confounding by smoking. The observation that for all the
identiﬁed CpGs except one the methylation levels are lower
in current smokers and rise to the levels of never smokers
with increasing time since quitting suggests that smoking
contributes to the methylation status of these CpGs, although
it might not be the only determinant and disentangling the
relation between smoking, methylation and lung cancer risk
might be challenging27.
Interestingly, for all the six CpGs identiﬁed the ORs for
lung cancer for former smokers are consistently lower than
ORs for current smokers. This observation, consistent across
all ﬁve studies, is intriguing but difﬁcult to explain. The anal-
yses by smoking have been adjusted for smoking intensity,
duration and time since quitting in former smokers, but we
cannot exclude that the result is due to misreported smoking
Table 4. Contribution to the ability to predict the risk of lung cancer by methylation level in addition to smoking status and smoking intensity
(pack-years)
cg05951221 cg21566642 cg05575921 cg06126421 cg233875691 cg03636183 All1
EPIC-Italy
mod1smoke 0.718 0.718 0.718 0.718 0.721 0.718 0.721
mod2smoke1M 0.758 0.751 0.784 0.769 0.725 0.758 0.797
AUCmod1-AUCmod2 0.040 0.033 0.066 0.051 0.004 0.040 0.076
p 0.017 0.040 0.001 0.005 0.548 0.009 2.64E-4
mod5smoke1pckyrs 0.789 0.789 0.789 0.789 0.791 0.789 0.791
mod6smoke1pckyrs1M 0.794 0.795 0.807 0.802 0.795 0.797 0.817
AUCmod3-AUCmod4 0.005 0.006 0.018 0.013 0.004 0.008 0.026
p 0.407 0.274 0.100 0.156 0.491 0.157 0.035
MCCS
mod3smoke 0.491 0.491 0.491 0.491 0.491 0.491 0.491
mod4smoke1M 0.569 0.584 0.586 0.603 0.599 0.572 0.640
AUCmod3-AUCmod4 0.078 0.093 0.095 0.112 0.108 0.081 0.149
p 0.018 0.003 0.003 2.68E-4 0.001 0.011 9.74E-7
mod5smoke1pckyrs 0.610 0.610 0.610 0.610 0.610 0.610 0.610
mod6smoke1pckyrs1M 0.621 0.626 0.624 0.641 0.640 0.624 0.665
AUCmod5-AUCmod6 0.011 0.016 0.014 0.031 0.030 0.014 0.055
p 0.315 0.205 0.232 0.038 0.048 0.234 0.002
All statistics have been calculated from logistic regression models adjusted for the matching variables specific to the study (see method section for
details). In EPIC-Italy smoking status is coded never, former and current. In MCCS it is coded never; former who stopped <10 years before blood
draw; former who stopped 10 or more years before blood draw; current smokers who smoked <15 cigarettes per day; current smokers who smoked
15 or more cigarettes per day.
1From the analyses including cg23387569 we have excluded two samples with missing values in the methylation level of this CpG.
Abbreviations: AUC, area under the curve.
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habits or residual confounding. It has been recently reported
that inﬂammation processes such as those caused by smoking
induce changes in the methylation proﬁle of natural killer
cells including hypomethylation in the AHRR gene28 for
which we observe associations with smoking and lung cancer
risk in our studies. The stronger associations observed in for-
mer smokers might reﬂect the activation of a persistent
immune response to smoking that continues and does not
resolve years after smoking cessation for selected ex-smokers
who develop lung cancer. Although the adjustment for cell
composition with the algorithm proposed by Houseman and
colleagues does not materially modify any of the observed
associations, the algorithm does not include all minor
immune cell fractions that might still have a role in con-
founding the results22.
Lung diseases, including lung cancer, may trigger an
immune response and alter the prevalence of speciﬁc cell
types in the blood29; it is therefore possible that the immune
response generated by undiagnosed lung cancer already pre-
sent for some cases at baseline may lead to differences in the
overall methylation proﬁle that could potentially explain our
ﬁndings. However, the possibility that the observed associa-
tions are because of the effect of subclinical lung cancer is
not supported by our data as the observed associations did
not change when the analyses were stratiﬁed by time between
blood draw and lung cancer diagnosis.
The observations that at cg23387569 the association
between methylation levels and smoking history was not evi-
dent or at least not as strong as for the other CpGs and that
for all CpGs the associations between DNA methylation lev-
els and lung cancer were not limited to current smokers sug-
gest that DNA methylation changes at these CpGs may play
a role in pathways to lung cancer that are independent of
smoking. Further studies speciﬁcally designed to increase the
number of lung cancer cases in never smokers are necessary
to provide convincing evidence to support this hypothesis.
The use of the Illumina Inﬁnium HumanMethylation 450
BeadChip allowed us to obtain epigenome-wide data at single
CpG resolution for a relatively large number of cases and
controls but these microarray data do not permit the system-
atic investigation of the regions surrounding the CpGs identi-
ﬁed to evaluate whether the observed associations may be
regional and thus have greater predictive power should a
more comprehensive measure of methylation be possible. In
the region on chromosome 2q.37.1, for example, two mea-
sured CpGs (cg21566642 and cg05951221) were both strong-
ly associated with lung cancer risk and others in the same
region show suggestive evidence of association. It is possible
Figure 2. Association between M methylation levels and lung cancer risk in the regions (100k bases) around the CpGs associated with lung
cancer risk (panels a–e represent regions in 2q37.1, 5p15.33, 6p21.33 and 12q14.1, respectively including the CpGs associated with lung
cancer risk).
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that methylation at other unmeasured sites in this region
might be even more strongly associated with lung cancer
risk. It is, therefore, important that further studies, for exam-
ple based on targeted bisulphite sequencing, are conducted to
ﬁnely map methylation in these regions.
To further investigate the functional relevance of the
observed associations it would be important to test whether
methylation in the CpGs identiﬁed alter the expression of
proximal genes. We could not do this directly in our cohorts
as we do not have gene expression data but we have investi-
gated it in other datasets and available public data. In a pre-
vious study we showed that methylation at cg05575921 was
associated with decreased expression of the AHRR gene both
in lung tumour tissue from current smokers and in mouse
models of exposure to cigarette smoking7.
For the three probes that map within a gene sequence
(cg05575921 in AHRR; cg23387569 in AGAP2; cg03636183 in
F2RL3) we investigated the correlation between methylation
and expression using TCGA (http://cancergenome.nih.gov/)
and HapMap (http://hapmap.ncbi.nlm.nih.gov/) data13. In the
latter, only data for the F2RL3-probe were available. In brief,
AHRR-probe methylation seems to be inversely correlated with
AHRR expression in lung tumour tissue from TCGA. F2RL3-
probe methylation does not show methylation-expression
correlation in TCGA data but HapMap data suggest a weak
inverse correlation (Pearson’s correlation coefﬁcient520.28,
p value< 0.01). AGAP2-probe methylation seems to be positive-
ly correlated with AGAP2 expression in both lung tumour tissue
from adenocarcinomas and squamous cell carcinomas (Pear-
son’s correlation coefﬁcient5 0.49, p value 0.025; and Pearson’s
correlation coefﬁcient5 0.55, p value5 0.15 respectively).
In the study within the ESTHER cohort, the authors esti-
mated that the gain in ability to discriminate between cases
and controls by adding methylation levels in cg03636183 in
the F2RL3 gene to a model that included smoking with pack-
years smoked was marginal (<1% increase in the AUC or
C-statistics)14. The analysis we conducted showed that the
inclusion of the methylation level of all 6 CpGs in the predic-
tion model produced an overall gain between 3% and 6% in
its discriminatory ability; the gain was as high as 8% to 13%
in former smokers. These ﬁndings encourage further work to
increase the sample size and genome coverage to identify fur-
ther regions with altered DNA methylation associated with
lung cancer risk and use this new information to improve
current risk prediction models for lung cancer especially in
former smokers and test the new models in terms of both
their ability to discriminate between cases and controls and
the accuracy of the predicted probabilities.
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